高温要求A1和大脑脊髓液中的巨细胞迁移抑制因子;从复发缓解转化为二级渐进性多发性硬化症的潜在标志物

相关实验视频

Updated: Aug 1, 2026

Detection of MicroRNAs in Microglia by Real-time PCR in Normal CNS and During Neuroinflammation

Detection of MicroRNAs in Microglia by Real-time PCR in Normal CNS and During Neuroinflammation

Published on: July 23, 2012

Simone Hjæresen¹, Eirikur Benedikz², Tobias Sejbaek³

¹University of Southern Denmark, Department of Molecular Medicine, Campusvej 55, 5230 Odense M, Denmark.

Journal of the neurological sciences

|January 26, 2024

概括

大脑脊髓液中高温要求血清蛋白酶 (HTRA1) /巨迁移抑制因子 (MIF) 的比率显示为多发性硬化症 (MS) 进展的生物标志物具有前途. 这个比率可以有效地区分复发性复发性多发性硬化症 (RRMS) 和继发性进展性多发性硬化症 (SPMS) 患者.

科学领域:

神经学神经学
生物标志物发现发现
免疫学免疫学免疫学

背景情况:

多发性硬化症 (MS) 诊断和治疗监测缺乏预测和预后生物标志物.
对于及时识别向二次渐进性MS (SPMS) 过渡的标志物,存在重大未满足的需求.

研究的目的:

评估大脑脊髓液 (CSF) 中高温要求血清蛋白酶 (HTRA1) /巨迁移抑制因子 (MIF) 的比例,以区分复发性复发性MS (RRMS) 和SPMS患者.
评估HTRA1/MIF比率作为MS进展的潜在生物标志物.

主要方法:

在健康对照组,RRMS患者 (治疗前和治疗后) 和SPMS患者 (治疗前和治疗后) 中,使用ELISA测量了MIF和HTRA1的CSF水平.
采用接收器运行曲线 (ROC) 分析来确定HTRA1/MIF比率的歧视力.

主要成果:

在未接受治疗的RRMS患者中,HTRA1/MIF比率升高,在基线时在SPMS患者中下降.
疾病修饰治疗 (DMT) 仅在RRMS患者中显著影响了该比率.
ROC分析显示,HTRA1/MIF比率可以从SPMS患者中区分先前未接受治疗的RRMS,灵敏度为91%和特异性为100%.

结论:

HTRA1/MIF比率是确定多发性硬化症中SPMS转化的一个强有力的候选生物标志物.
这种生物标志物有可能改善MS进展的诊断和监测.

关键词:

生物标志物生物标志物一个HTRA1的HTRA1.多元期权基金和多元期权基金.多发性硬化症是多发性硬化症.二次进展的二次进展.

更多相关视频

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

Flow Cytometric Analysis of Lymphocyte Infiltration in Central Nervous System during Experimental Autoimmune Encephalomyelitis

Flow Cytometric Analysis of Lymphocyte Infiltration in Central Nervous System during Experimental Autoimmune Encephalomyelitis

Published on: November 17, 2020

相关概念视频

Multiple Sclerosis l: Introduction

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...